XKDCT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XKDCT-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XKDCT023 is under development for the treatment of CD19 positive recurrent or refractory diffuse large B cell lymphoma, solid tumor, lung cancer, ovarian cancer, esophageal cancer, stomach cancer, pancreatic cancer, endometrial cancer, cervical cancer, breast thyroid cancer, colorectal cancer, prostate cancer. The therapeutic candidate comprises T-cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19.
Shenzhen Xiankangda Life Sciences overview
Shenzhen Xiankangda Life Sciences (Xiankangda Life Sciences) operate in healthcare sector. Xiankangda Life Sciences is headquartered in Shenzhen, Guangdong, China.
For a complete picture of XKDCT-023’s drug-specific PTSR and LoA scores, buy the report here.